Boston Advisors Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Boston Advisors reduced its stake in Eli Lilly and Co by 12.9% during the most recent quarter end. The investment management company now holds a total of 636,084 shares of Eli Lilly and Co which is valued at $49,506,418 after selling 94,170 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Eli Lilly and Co makes up approximately 1.21% of Boston Advisors’s portfolio.

Eli Lilly and Co opened for trading at $77.1 and hit $77.94 on the upside on Friday, eventually ending the session at $77.83, with a gain of 0.59% or 0.46 points. The heightened volatility saw the trading volume jump to 26,97,164 shares. Company has a market cap of $86,087 M.

Other Hedge Funds, Including , Wealth Enhancement Advisory Services boosted its stake in LLY in the latest quarter, The investment management firm added 640 additional shares and now holds a total of 14,161 shares of Eli Lilly and Co which is valued at $1,102,151. Eli Lilly and Co makes up approx 0.22% of Wealth Enhancement Advisory Services’s portfolio.Parasol Investment Management boosted its stake in LLY in the latest quarter, The investment management firm added 125 additional shares and now holds a total of 525 shares of Eli Lilly and Co which is valued at $40,861. Eli Lilly and Co makes up approx 0.04% of Parasol Investment Management’s portfolio. Mitchell Sinkler Starrpa sold out all of its stake in LLY during the most recent quarter. The investment firm sold 2,475 shares of LLY which is valued $186,937.Grassi Investment Management boosted its stake in LLY in the latest quarter, The investment management firm added 4,549 additional shares and now holds a total of 111,060 shares of Eli Lilly and Co which is valued at $8,388,362. Eli Lilly and Co makes up approx 1.64% of Grassi Investment Management’s portfolio.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.